Skip to main content

7206 GET INVOLVED STUDIES 7206 Therapeutic Studies in Porphyria Cutanea Tarda

Therapeutic Studies in Porphyria Cutanea Tarda

In order to participate in a study, you must personally
 contact EDRIN @ APF 1/866/APF/3635

Status: Recruiting


Porphyria Cutanea Tarda (PCT) is the most common porphyria that is generally diagnosed in adulthood. It is also the most responsive type of porphyria to treat. There are two current treatments for PCT. The first and more common treatment is repeated phlebotomies (removing blood, but that also includes the potential disadvantages of discomfort, inconvenience and expense. The second options is a low-dose treatment with medications that are normally used to treat malaria-- hydroxychloroquine or chloroquine. This treatment maybe more convenient and cost-effective but it is not option prescribed as primary treatment. This study compares these two treatments.
The research questions are:
  1. Is a low-dose regimen of hydroxychloroquine effective as phlebotomies for PCT treatment?
  2. Are people treated with low-dose hydroxychloroquine more likely to have relapses of their PCT?
This study compares two treatments for PCT. The first phase of the study is when patients get the treatment, either phlebotomies or hydroxychloroquine. During this phase study visits are every 2-4 weeks. After the treatment phase when participants have reached remission participants will meet with their doctor every 3-6 months, for 3 years to see if any symptoms return. The procedures done at these visits include physical exams, standard lab work such as checking iron levels, and lab work to look for porphyrin levels in the blood and urine.
A total of 100 patients with well-documented PCT will be enrolled in this study.
For each visit, you will be asked to:
  • Keep a log of your study medication if you are treated with hydroxychloroquine
  • Fill out a questionnaire about your PCT symptoms
  • Give a blood sample
    • 1 to 2 teaspoons if you are treated by hydroxychloroquine
    • 1 unit (450 ml, which is approximately 1 pint) of blood at regular intervals if you are treated with phlebotomy.
  • Give a urine sample
  • Have your local doctor’s office send us medical records and lab results

Targeted Enrollment

To be eligible to participate, you must:
  • Be at least 18 years old
  • Have well-documented PCT
  • Be able to provide consent to participate after you are informed about what the study includes
  • Be willing to avoid becoming pregnant during treatment; if you are a woman capable of becoming pregnant, you must use an effective contraceptive method
You are not eligible to participate if you have:
  • Your skin problem is not due to PCT, or is due to another type of porphyria
  • You are pregnant or if you plan to become pregnant during treatment
  • You have had prior treatment by phlebotomy, hydroxychloroquine or chloroquine within one month of starting this study. The exception to this is if you have  specific medical records and lab results from before and during the treatment
  • You are unwilling or unable to comply with study procedures and visit schedule
  • You have participated in this study before


Popular posts from this blog

Amazing patient advocacy....and needed media for this issue. Thank you Terri Witter!


What could it be?
Nerve Pain WHAT IS NEUROPATHIC PAIN? Neuropathic or nerve pain (NP) is a long-term or chronic pain disease that results from nerve damage. It can be caused by different diseases or conditions. Worldwide nerve pain affects as many as 26 million people. Neuropathic or nerve pain may affect larger areas of the body or it can be restricted to a smaller area, in this case it is called localized neuropathic pain (LNP). WHAT CAUSES NEUROPATHIC PAIN? Neuropathic or nerve pain may occur in the absence of an obvious visible cause (e.g. an accident, an injury, a chemical burn). There are several external situations that can directly damage nerves and lead to neuropathic pain, such as: Amputation of a limb (phantom pain, stump pain)Surgery (scar pain, post-surgery pain)Trauma or accident Neuropathic pain is also a common complication of other diseases, including nerve damage after shingles or herpes zoster infection (postherpetic neuralgia or PHN), nerve damage after HIV infectio…


GLOBAL PORPHYRIA ALLIANCE The APF is proud to support our members that live across the globe. Many countries around the world have developed organizations to support their local communities. We hope that enjoy the same opportunity to communicate with one another, develop friendships, and learn about porphyria. Here are links to patient advocacy groups worldwide that offer support to individuals impacted by porphyria. Argentina: Centro de investigaciones sobre porfirinas y porfirias | More informationAustralia: Porphyria Association, Inc. | More informationBrazil: Associação Brasileira de Porfiria | More informationCanada: Canadian Association for Porphyria | More informationColombia: Fundación Colombiana Para La Porfiria | More informationDenmark: (Porphyria Association Denmark)Denmark: (Danish Porphyria Support Group)England: British Porphyria AssociationFinland: Finnish Porphyria Support Group France: Association Française des Malades Atteints de Por…